A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational
- Sponsors Eisai Inc
- 02 Aug 2019 Planned End Date changed from 30 Sep 2019 to 30 Sep 2022.
- 02 Aug 2019 Planned primary completion date changed from 30 Sep 2019 to 8 Aug 2020.
- 17 Jul 2019 Planned End Date changed from 30 Jun 2019 to 30 Sep 2019.